Skip to main content

Ciphergen s Revenues Down, Losses Narrowed During Q2

NEW YORK, July 30 (GenomeWeb News) - Ciphergen Biosystems yesterday reported sliding revenues and narrowed losses for the second quarter.


The company booked $10.8 million in revenues for the quarter, down from $14.3 million during the same quarter in 2003.


R&D costs decreased to $6 million, from $7 million during the same quarter last year.


The company's net loss amounted to $13.1 million, down from $15.6 million during the second quarter a year ago. Last year's net loss included a $7.3 million non-recurring litigation settlement.


As of June 30, Ciphergen had $29.8 million in cash, cash equivalents and investments in securities.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.